Please use this identifier to cite or link to this item:
Title: Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
Authors: Sánchez-Muñoz, Alfonso
Vicioso, Luis
Santonja, Angela
Álvarez, Martina
Plata-Fernández, Yéssica
Miramón, José
Zarcos, Irene
Ramírez-Tortosa, César L
Montes-Torres, Julio
Jerez, José M
de Luque, Vanessa
Llácer, Casilda
Fernández-De Sousa, Cristina E
Pérez-Villa, Lidia
Alba, Emilio
metadata.dc.subject.mesh: Adult
Aged, 80 and over
Biomarkers, Tumor
Breast Neoplasms, Male
Carcinoma, Ductal, Breast
Middle Aged
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
Young Adult
Issue Date: 6-Oct-2017
Abstract: Male breast cancer is a rare disease that is still poorly understood. It is mainly classified by immunohistochemistry as a luminal disease. In this study, we assess for the first time the correlation between molecular subtypes based on a validated six-marker immunohistochemical panel and PAM50 signature in male breast cancer, and the subsequent clinical outcome of these different subtypes. We collected 67 surgical specimens of invasive male breast cancer from four different Spanish pathology laboratories. Immunohistochemical staining for the six-marker panel was performed on tissue microarrays. PAM50 subtypes were determined in a research-use-only nCounter Analysis System. We explored the association of immunohistochemical and PAM50 subtypes. Overall survival and disease-free survival were analyzed in the different subtypes of each classification. The distribution of tumor molecular subtypes according PAM50 was: 60% luminal B, 30% luminal A and 10% human epidermal growth factor receptor 2 (Her2) enriched. Only one Her2-enriched tumor was also positive by immunohistochemistry and was treated with trastuzumab. None of the tumors were basal-like. Using immunohistochemical surrogates, 51% of the tumors were luminal B, 44% luminal A, 4% triple-negative and 1% Her2-positive. The clinicopathological characteristics did not differ significantly between immunohistochemical and PAM50 subtypes. We found a significant worse overall survival in Her2-enriched compared with luminal tumors. Male breast cancer seems to be mainly a genomic luminal disease with a predominance of the luminal B subtype. In addition, we found a proportion of patients with Her2-negative by immunohistochemistry but Her2-enriched profile by PAM50 tumors with a worse outcome compared with luminal subtypes that may benefit from anti-Her2 therapies.
metadata.dc.identifier.doi: 10.1038/modpathol.2017.129
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.